MSL
PETX

Mackay Shields LLC’s Aratana Therapeutics, Inc. PETX Stock Holding History

Mackay Shields LLC’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-112,300
Closed -$404K – 1568
2019
Q1 		$404K Buy
112,300
+74,100
+194% +$321K ﹤0.01% 1226
2018
Q4 		$234K Buy
+38,200
New +$233K ﹤0.01% 1286

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Mackay Shields LLC's PETX Position: Q2 2019 in Review

Mackay Shields LLC sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 112,300 shares — an estimated $404K sold.

Mackay Shields LLC first reported a position in PETX in Q4 2018 and held it in 2 quarters. The position peaked at $404K in Q1 2019. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

  • Mackay Shields LLC reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Mackay Shields LLC sold 112,300 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $404K.
  • Mackay Shields LLC first reported a position in Aratana Therapeutics, Inc. in Q4 2018 and held it in 2 quarters.
  • Mackay Shields LLC's Aratana Therapeutics, Inc. position peaked at $404K in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Mackay Shields LLC's 13F filing for Q2 2019, filed 13 Aug 2019.